Why Braveheart Bio, Inc.’s (BRVE) Stock Is Down 12.11%
As of Thursday, November 05, Braveheart Bio, Inc.’s BRVE share price has dipped by 12.11%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Commentary & Analysis
Why Braveheart Bio, Inc.’s (BRVE) Stock Is Down 7.95%
As of Wednesday, November 04, Braveheart Bio, Inc.’s BRVE share price has dipped by 7.95%, which has investors questioning if this is right time to buy.Michael Rose
Why Braveheart Bio, Inc.’s (BRVE) Stock Is Up 6.82%
As of Tuesday, October 20, Braveheart Bio, Inc.’s BRVE share price has surged by 6.82%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Braveheart Bio, Inc.’s (BRVE) Stock Is Down 5.55%
As of Monday, October 05, Braveheart Bio, Inc.’s BRVE share price has dipped by 5.55%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Braveheart Bio, Inc.’s (BRVE) Stock Is Up 6.88%
As of Thursday, October 01, Braveheart Bio, Inc.’s BRVE share price has surged by 6.88%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,518.3 | $419.8 | 51% |
|
| Shares Out (Mil) | 7.4 | 43.5 | 18% |
|
| Institutional Ownership | 19.5% | 80.9% | 9% |
|
| Float (Mil) | 12.7 | 46.7 | 22% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 485 | 281 | 57% |
|
| Price Change (52-week) |
na | 53.5% | na |
|
| Growth | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (1.8%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $301 | na |
|
| Net Income (TTM) (Mil) | ($95) | ($11) | 11% |
|
| EPS (TTM) | ($14.684) | ($0.600) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($24) | ($6) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 12% |
|
| Enterprise Value (Q1) (Mil) | $1,707 | $446 | 47% |
|
| Valuation | BRVE | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.01 | na |
|
| P/E | na | 21.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.7% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | (149.4%) | (22.2%) | 3% |
|
| ROE | 197.8% | (21.5%) | 98% |
|
| Liabilities to Assets | 7.4% | 31.5% | 4% |
|
| F-Score | 1 | 3 | na |
|
Braveheart Bio, Inc. did not pass any screens on 11/6/2026.
